Drug
Ladiratuzumab Vedotin
Ladiratuzumab Vedotin: highest development phase Phase 1/2, developed by Seagen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Seagen
Trials
| Drug | Phase | Indication |
|---|---|---|
| ladiratuzumab vedotin NCT03310957 | Phase 1/2 | Triple Negative Breast Neoplasms |
Latest
No recent events.
Follow Ladiratuzumab Vedotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.